Back to Search
Start Over
RC-3095, a bombesin/gastrin-releasing peptide receptor antagonist, impairs aversive but not recognition memory in rats
- Source :
-
European Journal of Pharmacology . Feb2004, Vol. 486 Issue 1, p35. 7p. - Publication Year :
- 2004
-
Abstract
- Bombesin and its mammalian equivalent, gastrin-releasing peptide (GRP), stimulate cell proliferation and are involved in the pathogenesis of several types of human cancer. Bombesin-like peptides also display neuroendocrine activities and regulate neural function. In the present study, we evaluated the effects of the bombesin/GRP receptor antagonist (d-Tpi6, Leu13 psi[CH2NH]-Leu14) bombesin-(6–14) (RC-3095), experimental antitumor drug, on memory in rats. Adult female Wistar rats were treated with an intraperitoneal injection of RC-3095 (0.2, 1.0 or 5.0 mg/kg) 30 min before training in either inhibitory avoidance or novel object recognition tasks. Retention test trials were carried out 1.5 (short-term memory) or 24 h (long-term memory) after training. RC-3095 at the doses of 0.2 or 1.0 mg/kg, but not at the dose of 5.0 mg/kg, impaired both short- and long-term inhibitory avoidance retention, but did not affect recognition memory. The memory-impairing effect of RC-3095 could not be attributed to alterations in sensorimotor functions. The results show that the antitumor drug/GRP antagonist RC-3095 impairs formation of aversive memory. [Copyright &y& Elsevier]
- Subjects :
- *BOMBESIN
*GASTRIN
*PEPTIDES
*CELL proliferation
Subjects
Details
- Language :
- English
- ISSN :
- 00142999
- Volume :
- 486
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- European Journal of Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 12044365
- Full Text :
- https://doi.org/10.1016/j.ejphar.2003.12.011